Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: The French genito-urinary group (GETUG) recommendations

被引：17
|
作者：
Langrand-Escure, J. [1 ]
de Crevoisier, R. [2 ,3 ]
Llagostera, C. [4 ]
Crehange, G. [5 ]
Delaroche, G. [1 ]
Lafond, C. [2 ,3 ]
Bonin, C. [6 ]
Bideault, F. [5 ]
Sargos, P. [7 ]
Belhomme, S. [7 ]
Pasquier, D. [8 ]
Latorzeff, I [9 ]
Supiot, S. [4 ]
Hennequin, C. [10 ]
机构：
[1] Inst Cancerol La Loire Lucien Neuwirth, 180 Bis,Ave Albert Raimond, F-42270 St Priest En Jarez, France
[2] Ctr Eugene Marquis, Dept Radiotherapie, Ave Bataille Flandres Dunkerque, F-35042 Rennes, France
[3] Inserm 1099, LTSI, 263 Ave Gen Leclerc, F-35042 Rennes, France
[4] Inst cancerol Ouest Rene Gauducheau, Blvd Jacques Monod, F-44805 St Herblain, France
[5] Ctr Georges Francois Leclerc, Dept Radiotherapie, 1 Ave Prof Marion, F-21000 Dijon, France
[6] CHU Jean Minjoz, Serv Radiotherapie, 3 Blvd Alexandre Fleming, F-25000 Besancon, France
[7] Inst Bergonie, Dept Radiotherapie, 229 Cours Argonne, F-33000 Bordeaux, France
[8] Ctr Oscar Lambret, Dept Radiotherapie, 3 Rue Frederic Combemale, F-59020 Lille, France
[9] Clin Pasteur, Dept Oncol Radiotherapie, Bat Atrium,1 Rue Petite Vitesse, F-31300 Toulouse, France
[10] Hop St Louis, Serv Cancerol Radiotherapie, 1 Ave Claude Vellefaux, F-75010 Paris, France
来源：
CANCER RADIOTHERAPIE | 2018年 / 22卷 / 02期
关键词：
Prostate cancer; Hypofractionation; Radiotherapy; Image-guided radiation therapy; Recommendations; CONVENTIONALLY FRACTIONATED RADIOTHERAPY; EXTERNAL-BEAM RADIOTHERAPY; INTENSITY-MODULATED RADIOTHERAPY; III RANDOMIZED-TRIAL; RADIATION-THERAPY; NON-INFERIORITY; PHASE-3; TRIAL; ACUTE TOXICITY; HIGH-RISK; ADENOCARCINOMA;
D O I：
10.1016/j.canrad.2017.11.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Considering recent phase III trials results, moderate hypofractionated radiotherapy can be considered as a standard treatment for low and intermediate risk prostate cancer management. This assessment call for a framework allowing homogeneous and reproducible practices in the different centers using this radiotherapy schedule. The French Genito-Urinary Group (GETUG) provides here recommendations for daily practice of moderate hypofractionated radiotherapy for prostate cancer, with indications, dose, fractionation, pre-treatment planning, volume of interest delineation (target volume and organs at risk) and margins, dose constraints and radiotherapy techniques. (C) 2018 Published by Elsevier Masson SAS on behalf of Societe francaise de radiotherapie oncologique (SFRO).
引用
收藏
页码：193 / 198
页数：6
相关论文
共 50 条
  • [1] Definition of lymph node areas for radiotherapy of prostate cancer: A critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU)
    Sargos, Paul
    Guerif, Stephane
    Latorzeff, Igor
    Hennequin, Christophe
    Pommier, Pascal
    Lagrange, Jean-Leon
    Crehange, Gilles
    Chapeth, Olivier
    de Crevoisier, Renaud
    Azria, David
    Supiot, Stephane
    Habibian, Muriel
    Soulie, Michel
    Richaud, Pierre
    CANCER TREATMENT REVIEWS, 2015, 41 (10) : 814 - 820
  • [2] Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group
    Lieng, Hester
    Hayden, Amy J.
    Christie, David R. H.
    Davis, Brian J.
    Eade, Thomas N.
    Emmett, Louise
    Holt, Tanya
    Hruby, George
    Pryor, David
    Shakespeare, Thomas P.
    Sidhomm, Mark
    Skala, Marketa
    Wiltshire, Kirsty
    Yaxley, John
    Kneebone, Andrew
    RADIOTHERAPY AND ONCOLOGY, 2018, 129 (02) : 377 - 386
  • [3] Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group
    Lieng, Hester
    Kneebone, Andrew
    Hayden, Amy J.
    Christie, David R. H.
    Davis, Brian J.
    Eade, Thomas N.
    Emmett, Louise
    Holt, Tanya
    Hruby, George
    Pryor, David
    Sidhom, Mark
    Skala, Marketa
    Yaxley, John
    Shakespeare, Thomas P.
    RADIOTHERAPY AND ONCOLOGY, 2019, 140 : 68 - 75
  • [4] Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology group
    Lapierre, Ariane
    Hennequin, Christophe
    Beneux, Amandine
    Belhomme, Sarah
    Ouaritini, Nicolas Benziane
    Biston, Marie-Claude
    Crehange, Gilles
    de Crevoisier, Renaud
    Dumas, Jean-luc
    Fawzi, Maher
    Lisbona, Albert
    Pasquier, David
    Pelissier, Sandra
    Graff-Cailleaud, Pierre
    Pommier, Pascal
    Sargos, Paul
    Simon, Jean-Marc
    Supiot, Stephane
    Tantot, Florence
    Chapet, Olivier
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 173
  • [5] PREDICTORS OF ACUTE GENITO-URINARY TOXICITY AFTER HIGH-DOSE PROSTATE CANCER RADIOTHERAPY: INITIAL RESULTS OF A PROSPECTIVE STUDY
    Carillo, Viviana
    Cozzarini, Cesare
    Rancati, Tiziana
    Muraglia, Alessandro
    Degli Esposti, Claudio
    Girelli, Giuseppe
    Vavassori, Vittorio
    Villa, Sergio
    Valdagni, Riccardo
    Fiorino, Claudio
    ANTICANCER RESEARCH, 2012, 32 (05) : 1955 - 1956
  • [6] Late genito-urinary morbidity after 3D conformal radiotherapy for prostate cancer: Absence of dose and dose-volume effect?
    Zapatero, A.
    Garcia Vicente, F.
    Floriano, A.
    Marin, A.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S424 - S424
  • [7] Hypofractionated radiotherapy recommendations for localized prostate cancer in Brasil
    Freitas Palhares, Daniel Moore
    Furbino Pimentel, Leonardo Cunha
    Castilho, Marcus Simoes
    da Costa, Andrea Barleze
    Reisner, Marcio Lemberg
    Kuhnen, Felipe Quintino
    Passaro, Anderson
    Teixeira Leite, Elton Trigo
    Costa Faustino, Fabio de Lima
    Obst, Fernando Mariano
    Barbosa Ferro Costa, Flavio Napoleao Buarque
    Pioner, Giovani Thomaz
    de Carvalho, Icaro Thiago
    Fernandes da Silva, Joao Luis
    Kokay Morikawa, Lisa Karina
    da Rocha Zanuncio, Pedro Henrique
    Hanriot, Rodrigo de Morais
    Rosa, Arthur Accioly
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2021, 67 (01): : 7 - 18
  • [8] Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group
    Sroussi, Marine
    Elaidi, Reza
    Flechon, Aude
    Lorcet, Marianne
    Borchiellini, Delphine
    Tardy, Magalie P.
    Gravis, Gwenaelle
    Guerin, Mathilde
    Laguerre, Brigitte
    Estrade, Florian
    Delva, Remi
    Barthelemy, Phillipe
    Loriot, Yohann
    Lavaud, Pernelle
    Lebret, Thierry
    Neuzillet, Yann
    Penel, Nicolas
    Houede, Nadine
    Pouessel, Damien
    Rousseau, Benoit
    Mussat, Elodie
    Gross-Goupil, Marine
    Culine, Stephane
    Gauthier, Helene
    Gobert, Aurelien
    Roupret, Morgan
    Huillard, Olivier
    Tartas, Sophie
    Radulescu, Camelia
    Allory, Yves
    Oudard, Stephane
    CLINICAL GENITOURINARY CANCER, 2020, 18 (04) : 295 - +
  • [9] Role of ACE Inhibitors in Genito-urinary toxicity following Curative Radiotherapy for Bladder Cancer
    Devi, Aarani
    Olowofela, Ayokunle
    Lodhi, Taha
    Hoskin, Peter
    Ballas, Leslie
    Choudhury, Ananya
    Kerns, Sarah L.
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S2587 - S2589
  • [10] Urachal carcinoma: a large retrospective multicentric study from the French Genito-Urinary Tumor Group
    Guerin, M.
    Miran, C.
    Colomba, E.
    Cabart, M.
    Herrmann, T.
    Pericart, S.
    Maillet, D.
    Neuzillet, Y.
    Deleuze, A.
    Coquan, E.
    Laramas, M.
    Thibault, C.
    Abbar, B.
    Mesnard, B.
    Borchiellini, D.
    Dumont, C.
    Boughalem, E.
    Deville, JL.
    Cancel, M.
    Saldana, C.
    Khalil, A.
    Baciarello, G.
    Flechon, A.
    Walz, J.
    Gravis, G.
    FRONTIERS IN ONCOLOGY, 2023, 13
12345